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Abstract: Since the discovery of the two-dimensional (2D) carbon material, graphene, just over
a decade ago, the development of graphene-based field effect transistors (G-FETs) has become
a widely researched area, particularly for use in point-of-care biomedical applications. G-FETs are
particularly attractive as next generation bioelectronics due to their mass-scalability and low cost of
the technology’s manufacture. Furthermore, G-FETs offer the potential to complete label-free, rapid,
and highly sensitive analysis coupled with a high sample throughput. These properties, coupled
with the potential for integration into portable instrumentation, contribute to G-FETs’ suitability for
point-of-care diagnostics. This review focuses on elucidating the recent developments in the field of
G-FET sensors that act on a bioaffinity basis, whereby a binding event between a bioreceptor and the
target analyte is transduced into an electrical signal at the G-FET surface. Recognizing and quantifying
these target analytes accurately and reliably is essential in diagnosing many diseases, therefore it
is vital to design the G-FET with care. Taking into account some limitations of the sensor platform,
such as Debye–Hükel screening and device surface area, is fundamental in developing improved
bioelectronics for applications in the clinical setting. This review highlights some efforts undertaken
in facing these limitations in order to bring G-FET development for biomedical applications forward.
Keywords: G-FET (graphene-based field effect transistors); DNA; aptamer; Debye length; antigen
binding fragment; Dirac voltage; point-of-care
1. Introduction
The discovery of Graphene in 2004 by Novoselov and Geim [1] brought with it many advances
in scientific research. Graphene is a single-atom-thick carbon sheet with sp2 bonded carbon arranged
in a honeycomb structure. The unique properties of graphene, including excellent conductivity, rapid
electron transport, large surface area, and biocompatibility [1,2], make it an attractive candidate for
energy, environmental, and healthcare applications [3]. The development of the first enzyme-based
biosensor by Clark and Lyons in 1962 [4] has resulted in vital biomedical devices, such as glucose
biosensors [5]. Biosensors are essentially comprised of two main components; a biorecognition molecule
(or capture molecule), and a signal transducer that determines the performance of the sensor. In the last
several years, numerous studies have developed a wide range of biosensor systems and transduction
techniques for the highly sensitivite detection of disease biomarkers. In particular, graphene biosensors
represent a rapidly expanding multi-disciplinary field due to their higher sensitivity, wide linear
detection ranges, and rapid detection, as the majority of disease biomarkers are typically present
at ultra-low concentrations at the onset of the disease or illness [6]. For example, graphene-based
biocatalytic sensors, such as enzyme biosensors, exhibit higher sensitivities owing to graphene’s
excellent electronic conductivity. On the other hand, an affinity-based sensor, such as an immunosensor,
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utilizes a surface-immobilized recognition probe to selectively interact with the biological analyte in
solution, and yields an electrical signal directly proportional to the analyte concentration.
Recent advances in the microfabrication techniques have led to the development of
next-generation bioelectronic devices, including silicon nanowires [7–10], carbon nanotubes [11–13],
and graphene-based field effect transistor (G-FET) devices for biosensor applications. This review
particularly focuses on graphene-based field effect transistor devices because of their functionalizable
surface and highly sensitive electronic properties. A G-FET is made up of a conducting graphene
channel across two metal contacts, the source and drain electrodes, through which the current is
conveyed. Here, the graphene is chemically functionalized with biomolecule receptors, such as
antibodies or single-strand DNA probes, which can selectively bind to the target biomolecules in
solution. The binding of target biomolecules to the graphene channel leads to a change in charge or
electric potential at the G-FET surface, resulting in a charge carrier density and mobility variation
within the G-FET, which leads to an electrical conductivity change associated with biomolecular
binding events. Thus, the chemically modified G-FET device transduces the biological signal into an
electrical signal at the bioelectronics interface upon each binding event [14]. Due to their ultrahigh
mobility [15], G-FETs respond rapidly to variations of gate-source voltage [16], enabling a unique and
powerful platform for detecting binding events.
G-FET biosensors are particularly attractive in point-of-care diagnosis due to their miniaturization,
potential for large-scale manufacture at low-cost, rapid and inexpensive assays, and reduced need
for skilled personnel. Moreover, G-FET biosensors offer the benefits of high sensitivity, lower
detection limits, low cost, and high throughput detection compared to the existing enzyme-linked
immunosorbent assay (ELISA), Polymerase Chain Reaction (PCR), and fluorescence methods, which
are time consuming and require expensive and complex optical imaging devices and sophisticated
image recognition software [16]. It is for these reasons that many G-FET biosensors have already been
developed and reported in the literature. In fact, conducting a search on the NCBI Pubmed Central
database using the words “graphene field effect transistors” flagged up 1501 entries. When widening
this search to “graphene biosensors”, over 2400 entries appeared. Many of these G-FETs include pH
sensors, enzyme-modified sensors, DNA-based sensors, and immunosensors [17].
This review is organized to emphasize the recent developments in affinity-based G-FET biosensors.
We will briefly discuss the properties of graphene functionalization techniques in the context of
bioelectronics in Section 2. Section 3 discusses affinity-based G-FET biosensors for the highly sensitive
detection of biomolecules.
2. Graphene Platform
2.1. Graphene Properties
Graphene, or single atomic thick carbon, is the first purely two-dimensional (2D) material to be
obtained [18]. Graphene is made up of carbon atoms which are bound to three others with a 120◦
bond angle, resulting in a hexagonal lattice arrangement of sp2-hybrised carbon [19]. The 2D nature
and hexagonal carbon arrangement is the basis of graphene’s high specific surface area (2630 m2/g),
a trait which is particularly advantageous in biosensing applications [20]. Graphene is considered
attractive for electronic applications due to its intrinsically exceptional ballistic charge transport [18].
Experimentally, carrier mobilities have been reported to be about 2 orders of magnitude larger than the
“gold-standard” semiconductor, silicon. Carrier mobilities have been known to exceed 107 cm2·V−1·s−1
in graphene that has been decoupled from bulk graphite, to be as high as 105 cm2·V−1·s−1 in
suspended graphene devices [21], and about 4 × 103 cm2·V−1·s−1 for CVD graphene on a SiO2
substrate. Moreover, graphene material can be manufactured in large quantities and relatively cheaply,
therefore making it a suitable substrate for large-scale electronic device manufacturing [22].
Graphene consists of two energy bands, the valence band (VB) and the conductance band (CB),
which hold holes and electrons, respectively [23]. The arrangement of the carbon atoms of graphene
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in a honeycomb lattice creates a completely full VB and an empty CB, as depicted in Figure 1 [19].
The two bands intersect at a point called a Dirac point, or the K and K’ points in the Brillouin zone.
At the point where they meet, depicted by the Dirac voltage (VD) in Vg–IDS measurements, the
Fermi level passes across. This Fermi level can be tuned and adapted because of doping by external
influences, such as electron deficient (p-doping) or electron rich (n-doping) molecules [18], therefore
essentially causing a shift in the VD to a more positive voltage (p-doping) or to a more negative voltage
(n-doping). The VD can therefore be monitored and utilized as a means of sensing biological molecules.
The electronic properties, such as the VD, carrier mobility, and resistance, can be influenced by many
external sources, these include: applying an electrical field, charged moieties near the graphene’s
surface, or by chemically modifying the surface, such as chemical binding to the graphene both
covalently and non-covalently [18].
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2.2. G-FET Development
Graphene FETs are generally fabricated using micro fabrication techniques, such as
photolithography coupled with metal evaporation or physical vapor deposition (PVD), to pattern and
develop the device contacts. The graphene is either then transferred from a copper substrate used for
its growth (CVD graphene) or from exfoliated graphene on to a patterned device [24]. Alternatively,
a bulk graphene layer (CVD graphene on SiO2/Si or epitaxial graphene) is plasma etched away to
form a channel [25]. Many G-FETs produced in this manner are highlighted in Table 1.
The channel is then modified to detect target biomarkers by immobilizing bioreceptors onto
the graphene channel. This can be done directly (adsorption) or through a linker molecule.
The immobilization of a highly specific bioreceptor (a process termed biofunctionalization) to the
graphene surface induces chemical specificity towards the target biomarker. Such receptors may
include amino acids, enzymes, antibodies, aptamers, or indeed any selective and specific molecule [26].
However, if a linker molecule is required, the graphene channel must first be chemically functionalized
to enable the immobilization of the bioreceptor. The chemical functionalization of graphene can be also
be used to tailor the electronic properties of graphene via doping and band-gap engineering effects,
produced by chemical modification or adsorption of molecules on to the graphene [18].
The functionalization of graphene with a linker molecule can be performed through covalent
binding to the carbon atoms of the hexagonal matrix or by non-covalent binding to the graphene
by electrostatic and/or weak Van der Waals forces [18]. A wide range of potential functionalization
chemistries, such as halogenation, hydroxylation, epoxidation, carboxylation, amination, alkylation,
and azidation, have been developed for graphene [27]. The presence of sp2 carbon atoms makes
the graphene surface a potential candidate for covalent bonding [28]. Covalent chemistries used to
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make graphene functional include fluorination [29] and hydrogenation [30] by plasma treatments.
Also utilized is free-radical addition to the carbon atoms of the hexagonal matrix [31], such as
diazotization [32]. Other covalent methods include the covalent attachment of polymers such as
PEG [31] and silanization by 3-aminopropyltriethoxysilane (APTES) [33]. Tehrani et al. demonstrated
the development of a G-FET for cancer risk biomarker (8-OHdG) with a limit of detection of
0.1 ng·mL−1 using the diazonium functionalization chemistry [34]. Teixeira and co-workers reported
the detection of human chorionic gonadotropin (hCG) at 0.62 ng·mL−1 using an epitaxial G-FET
functionalized using the APTES method [33]. Although covalent chemistry has proven to be successful,
it also creates undesirable disruption to the sp2 nature of the carbon atoms. As a result, the sp2
hybridization will be converted to sp3 hybridization [28], which disrupts the electron structure of
graphene, and therefore diminishes the excellent and desirable electronic properties of graphene.
Therefore, other avenues of graphene functionalization have been explored [18].
Non-covalent functionalization is dominated by the physisorption of molecules to the graphene
through weak Van de Waals forces [18]. More specifically, this non-covalent functionalization often
occurs through an interaction between the pi-electron cloud of the graphene and the functional
molecule, otherwise known as pi–pi stacking. Graphite (bulk graphene) is an example of pi–pi
interaction. Graphite is multiple layers of graphene sheets stacked upon one another through
an interaction between their respective pi-electron clouds [31]. Since this non-covalent functionalization
of graphene occurs in this way, the sp2 nature of the carbon atoms is not affected. Therefore, the
electronic and structural properties are not severely disrupted [18], making this a desirable method of
functionalization for G-FET biosensor development. Often, the molecule used for functionalization has
a polyaromatic hydrocarbon base, such as benzene, naphthalene, or pyrene, with pyrene exhibiting
a strong affinity towards graphene through pi-stacking [35]. Chen et al. demonstrated the effect of some
of these electron withdrawing and electron donating molecules on the graphene’s electronic properties.
It was reported that functionalization with tetrafulvalene (TTF), an electron donor, acts to p-dope the
graphene, whilst an electron acceptor, hexaazatriphenylene-hexacarbonitrile (HATCN), acts to n-dope
the graphene. However, both remained non-destructive to the graphene’s electronic and structural
properties [18]. Furthermore, functionalizing the graphene surface using a pyrenebutanoic acid
succinimidyl ester (PBASE) through pi-stacking is attractive, as the pyrene base of this molecule exhibits
a strong affinity to the graphene sheet, whilst the succinimidyl ester provides a binding site for amines
of various biomolecules, including antibodies, enzymes, bacteria, and nucleic acid probes [25,36–40].
Moreover, several non-covalent functionalization techniques have been developed to decorate the
graphene surface using metal nanoparticles, such as gold [41], platinum [42], palladium [43], and
zinc oxide [44]. Metal nanoparticles can be deposited onto the graphene channels by immersing
the channel into the metal salt solution, electrochemical deposition, or by a chemical reduction
process. Gutes et al. reported that the nature of the metal dictates the size and densities of the
as-prepared metal nanoparticles, despite the same experimental conditions. For example, platinum
metal appeared to form smaller particles with lower density when compared to gold and palladium [43].
Cai et al. utilized gold nanoparticles on a G-FET to create a binding site for a sulphur-terminated
biorecognition molecule. Moreover, Cai et al. reported the presence of nanoparticles to increase the
active surface area of the G-FET, which in turn improved the sensitivity by providing more binding
sites for biomolecule immobilization [41].
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Table 1. A list of graphene-based field effect transistor (G-FET) biosensors currently reported in the literature.
Type of Sensor Target Application Substrate Detection Method Detection Limit Control Signal-to-Noise Ref.
Nucleic acid 22-mer DNA Proof-of-concept 2 × 2.5 cm CVD graphene onSiO2, Cr/Au contacts
Back gated,
DNA probe 100 pM One-base mismatched - [25]
20-mer DNA Proof-of-concept 45 × 90 µm CVD on SiO2/Si,Cr/Au contacts
Liquid gated,
DNA probe 10 pM One-base mismatched - [37]
22-mer DNA Proof-of-concept 4 µm CVD graphene channelon SiO2/Si, Ti/Au contacts
Liquid gated,
PNA probe 10 fM
One-base mismatched,
non-complementary 3 [39]
22-mer miRNA (Let7g) Cancer 45 × 90 µm CVD on SiO2/Si,Cr/Au/Cr contacts
Liquid Gated.
RNA probe 100 fM Non-complementary miRNA - [45]
22-mer miRNA (Let7b) Cancer
rGO on SiO2/Si, Decorated
with Au nanoparticles
(AuNPs)
Liquid gated,
PNA probe 1 fM
One-base mismatched and
non-complementary 3 [41]
Immunosensor Brain natriuretic peptide(BNP) Heart failure
rGO on SiO2/Si, Decorated
with PtNPs
Liquid gated,
Anti-BNP 100 fM BSA, D-Dimer, and HSA 3 [46]
Carcinoembryonic antigen
(CEA) Cancer
25 × 50 µm CVD on SiO2/Si,
Ti/Au contacts
Liquid-gated,
Anti-CEA 0.5 pM - - [47]
Human Chorionic
Gonadotropin (hCG) Pregnancy
Epitaxial on SiC,
Ti/Au contacts I-V, Anti-hCG 16.7 pM Urea and Cortisol - [33]
8-hydroxydeoxyguanosine
(8-OHdG) Cancer
250 µm × 3 mm Epitaxial on
SiC, Ti/Au contacts I-V, Anti-8-OHdG 0.35 nM PBS no 8-OHdG - [34]
Protective antigen (PA) Anthrax GO nanosheets on glass,Ti/Au contacts
Liquid gated,
PA65 5–12 aptamer 12 aM - - [48]
rGO—reduced graphene oxide, PNA—peptide nucleic acid, BSA—bovine serum albumin, HSA—human serum albumin.
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3. G-FET-Based Nucleic Acid Sensors
Nucleic acids such as deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and microRNA
(miRNA) play a major role in human physiology, and therefore they also play a major role in many
diseases. As a result, rapid and highly sensitive detection methods of nucleic acid abnormalities
or expression are considered extremely important for disease diagnosis [39]. G-FETs for DNA tend
to be more sensitive and therefore more responsive to target analytes than the widely researched
and developed ion-sensitive FET, which is attributed to the difference in the sensing mechanisms.
Nucleic acids in close proximity with the graphene surface, whether physisorbed or through
hybridization events, considerably change the graphene’s electronic properties by doping the graphene.
This causes a direct change to the graphene’s properties. The standard bulk ion-sensitive FET,
however, responds to changes in external charges, which cause a change in the channels’ capacitive
properties [45]. In the case of nucleic acid-based biosensors, the biorecognition molecule is often
a nucleic acid probe, as depicted in Figure 2.
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3.1. DNA Sensor
DNA, a double stranded polynucleotide, contains the entire genetic code of an individual,
therefore assessing an individual’s genetic makeup can not only aid in the diagnosis of many
diseases, but also contains information regarding an individual’s predisposition to genetic diseases
and cancers. The DNA nucleotide is made up of a phosphate group, which makes the backbone
of the DNA polynucleotide, a sugar (2-deoxyribose), and a nucleobase (adenine = A, guanine = G,
thymine = T, and cytosine = C). These nucleotides arrange in specific sequences through phosphodiester
bonding between nucleotides to make up the genome, which stores and transmits genetic information.
A complementary strand of DNA then binds via the hydrogen bonding of the nucleobases (A with
T and G with C) to make it a double-stranded helix [49]. Since DNA contains important genetic
information, it is highly important to develop rapid, specific, and sensitive methods of detection
for DNA. Developing such tests will aid considerably in disease diagnosis, genetic screening [41],
pharmacogenomics, molecular diagnostics, drug discovery, and potentially prevention by enabling
early treatment [25].
Over the past decade, several biosensor techniques have been developed for the high sensitivity
detection of DNA. Several G-FET-based DNA biosensors have been developed using various sensing
methods, including electrochemical [50], back-gated G-FETs [25], and liquid-gated G-FETs [45].
DNA-based G-FETs follow conventional DNA detection mechanisms. Short DNA oligomers (DNA probes)
are used for biorecognition. DNA probes are short nucleotides which are complementary to the target
DNA. These DNA probes are either immobilized to the sensor surface and act as a capture probe for the
target DNA [38,51], or they are tagged and bound secondarily to target DNA captured on the sensor
surface [50]. Alternatively, DNA can also be detected by physisorption, as the nucleobases which
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make up DNA are aromatic carbons, and thus are able to bind to the graphene via pi-stacking [52].
Ping et al. demonstrated a scalable (>90% yield) back-gated G-FET DNA biosensor with 1 fM
sensitivity for a 60-mer DNA. The G-FET was fabricated by transferring CVD-grown graphene onto
a pre-fabricated SiO2 substrate with 45 nm thick Cr/Au contacts by an electrolysis bubbling method.
Using a PBASE linker, the 22-mer DNA probe was attached to the graphene surface. It was reported
that the Dirac peak of the graphene shifted increasingly at each stage of functionalization (highlighted
in Figure 3) and furthermore with increasing DNA concentration. Ping et al. also confirmed the high
selectivity of the probe by applying a single-nucleotide mismatched DNA strand and a non-complementary
DNA strand. The application of the one-base mismatched DNA to the sensor resulted in a signal change
only 12% of that of the complementary DNA [25].
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Figure 3. (a) I-Vg characteristics of a G-FET proposed by Ping et al., highlighting the change in
electronic characteristics at each stage of the functionalization and detection process. (b) Dirac voltage
shift of increasing concentrations of DNA oligomers of different lengths fitted using the Sips model.
Adapted from [25]. Copyright 2016 by the American Chemical Society.
Many genetic-related diseases are caused by an abnormality in DNA expression or genetic
information. Therefore, it is not only important to develop sensors to detect aberrant expression
but also abnormalities in the genetic code. Abnormalities exist as mutations in the genetic sequence.
The most common of these mutations is known as a single nucleotide polymorphism (SNP), otherwise
known as a single nucleotide mutation in the DNA sequence [53]. These mutations can have a dramatic
effect on an individual’s health. SNPs have previously been reported to be involved in the development
of cancers and genetic disorders. Hwang and co-workers have reported the development of a highly
specific and sensitive SNP detection using a G-FET. The G-FET reported in this work acted on
a strand displacement principal, which is a method employed widely across the medical profession.
A double-stranded DNA (dsDNA) probe was immobilized upon the CVD-based G-FET surface via
PBASE. One strand of this dsDNA is the complementary sequence to the target DNA. The second strand
was essentially the same sequence as the target DNA; however, four guanine bases were substituted
with inosine bases to weaken the binding affinity between the two strands. On exposure of the G-FET
to the target DNA containing an SNP and the perfect match DNA, the inosine modified strand was
displaced. The perfectly complementary target DNA exhibited a VD shift of −50 mV by n-doping for
100 µM DNA and −11.6 mV for 100 µM target DNA containing an SNP. Hwang et al. demonstrated
a G-FET which can discriminate the target DNA and DNA containing an SNP. This discrimination
was reported to be possible over a range of concentrations, from 100 nM to 100 µM, as highlighted in
Figure 4a–c. In addition, a direct quantification of each target DNA type was illustrated by a change in
the resistance of the graphene channel, as depicted in Figure 4d [38].
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probe was immobilized upon the graphene surface. A biotinylated bovine serum albumin (BSA) was 
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to 100 fM of the target miRNA, a noticeable negative shift was observed due to the electron doping 
effect of DNA hybridization on the graphene channel. Xu et al. also confirmed the selectivity of their 
devices by applying a control nucleotide to the sensor. The response seen for the control nucleotide 
was negligible when compared to the response exhibited by the hybridization event, which occurred 
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3.2. miRNA Sensor
MicroRNAs are short chain RNAs consisting of approximately 22 nucleotides. miRNAs have
previously been reported to be closely related to many diseases, including cancer. The link between the
development and pathogenesis of these diseases and miRNAs has been said to occur when the miRNA
expression deviates away from the normal standard [55]. miRNAs are encoded within the genome
and act to downregulate gene expression, a role which is vital for the homeostasis of the human body.
miRNAs downregulate gene expression by either one of two methods: mRNA cleavage or translational
repression. Since the role of miRNA in maintaining normal levels of gene expression is vital to human
physiology and function, a deviation away from this leads to disease development, including human
cancers [56]. In 2014, Xu et al. [45] demonstrated the successful development of a G-FET specific
for let7g, a miRNA widely believed to play a role in tumour suppression. Xu et al. produced the
G-FET using CVD graphene transferred onto a SiO2/Si substrate with Cr/Au/Cr contacts, and applied
a polydimethylsiloxane (PDMS) microfluidic to avoid contact interference in the signal. Using the well
documented streptavidin-biotin binding mechanism, the 41-mer DNA probe was immobilized upon
the graphene surface. A biotinylated bovine serum albumin (BSA) was absorbed onto the channel, and
streptavidin was then bound to that biotinylated BSA. The DNA probe (also biotinylated) was then
introduced, and was able to immobilize upon the channel via binding to one of the three remaining
binding sites on the streptavidin. On exposing the eight G-FETs to 100 fM of the target miRNA,
a noticeable negative shift was observed due to the electron doping effect of DNA hybridization on
the graphene channel. Xu et al. also confirmed the selectivity of their devices by applying a control
nucleotide to the sensor. The response seen for the control nucleotide was negligible when compared
to the response exhibited by the hybridization event, which occurred between the probe and the target
miRNA (highlighted in Figure 6) [45].
Cai et al. demonstrated enhanced sensitivity by addressing two of the previously mentioned
influential factors on G-FET sensitivity. Firstly, Cai et al. exchanged the DNA probe for a peptide
nucleic acid (PNA) probe. PNA is essentially the same as DNA, however due to the exchange of
the deoxy-ribose and phosphate backbone for a peptide backbone it is essentially a neutral form of
DNA. However, PNA is still able to exhibit an effect on the graphene’s doping due to the electron-rich
nucleobase. Therefore, it is still possible to note a shift in the VD of the graphene. The advantage of
using a PNA probe, as reported by Cai and co-workers, was the diminished repulsion between DNA
molecules caused by the negative backbones of the DNA, therefore enhancing the hybridization’s
efficiency. Secondly, Cai et al. reported a G-FET decorated with AuNPs with a lower limit of detection
of 1 fM (highlighted in Figure 7). The PNA probe was immobilized onto the AuNPs by a cysteamine
and glutaraldehyde binding step. Decorating the graphene surface with AuNPs reportedly improved
the sensitivity by 1 order of magnitude when compared to a G-FET which was not decorated with
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AuNPs. The improvement noted in sensitivity was attributed to the significant increase in surface area
from the addition of the AuNPs [41].
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Detection then occurs when the target analyte binds to the antigen binding fragment of the antibody, 
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Lei and co-workers reported the successful detection of a protein biomarker in whole blood, 
which is specific to heart failure, using a platinum nanoparticle (PtNP) decorated rGO-FET 
immunosensor technology. The binding of brain natriuretic peptide (BNP) to anti-BNP was able to 
be detected through liquid gated measurements at 100 fM. Adding to this, the BNP was able to be 
distinguished from whole blood proteins, namely, human serum albumin and D-Dimer. 
Furthermore, BNP was successfully detected in a whole blood sample treated with a microfilter, 
reported in Figure 9. This indicated that the immunosensor was capable of distinguishing BNP from 
other proteins within the complicated sample matrix of whole blood [46]. 
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I unoassays are bio olecular recognition tests co only used to deter ine the presence of
bio arkers in a solution and potentially quantify them. More specifically, immunoassays are analytical
Diagnostics 2017, 7, 45 11 of 18
techniques which rely on biorecognition by antibody-antigen interactions. Therefore, the techniques are
based on the specificity and affinity of the antibody for the respective antigen [57]. Immunosensors are
developed by the immobilization of an antibody onto the G-FET’s surface. Detection then occurs
when the target analyte binds to the antigen binding fragment of the antibody, as depicted in Figure 8.
Many G-FETs for immunoassays have been reported in the literature [33,34,46,47].
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Figure 8. A schematic representation of the process flow for developing an immuno-based G-FET.
Gold—Contact pads, dark grey—SiO2, light grey—graphene, purple—surface functionalisation.
Lei and co-workers reported the successful detection of a protein biomarker in whole blood, which
is specific to heart failure, using a platinum nanoparticle (PtNP) decorated rGO-FET immunosensor
technology. The binding of brain natriuretic peptide (BNP) to anti-BNP was able to be detected through
liquid gated measurements at 100 fM. Adding to this, the BNP was able to be distinguished from whole
blood proteins, namely, human serum albumin and D-Dimer. Furthermore, BNP was successfully
detected in a whole blood sample treated with a microfilter, reported in Figure 9. This indicated that
the immunosensor was capable of distinguishing BNP from other proteins within the complicated
sample matrix of whole blood [46].Diagnostics 2017, 7, 45  12 of 18 
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screening is a phenomenon caused by the solution’s interaction with the sensor [17]. Ionic solutions 
effectively screen the charge of analytes in proximity with the sensor surface by forming an electron 
double-layer. The length at which the analyte is able to be screened, otherwise known as the Debye 
screening length (λD), is highly dependent on buffer concentration [52]. Therefore, immunoFET 
detection is essentially limited to interactions which occur within a small distance of the electrode 
surface. Molecules outside of the λD are generally unable to be detected, as the charges within the 
graphene channel are unaffected [58]. As depicted in Figure 11, the λD decreases with increasing 
buffer concentration [17]. The Debye screening phenomenon makes it difficult to develop a highly 
Figure 9. (a) Transfer curves of a PtNPs-decorated rGO-FET in response to brain natriuretic peptide
(BNP) in whole blood samples which have been treated with a microfilter; (b) Dirac voltage shift in
response to the differing concentrations of BNP. Adapted from [46], Copyright 2017, with per ission
fro Elsevier.
In 2017, Zhou et al. demonstrated the development of a G-FET for the real-time monitoring of
carcinoembryonic antigen (CEA) detection, a biomarker for cancer. Zhou and co-workers reported
a detection limit of 100 pg/mL (0.5 pM), far exceeding that of the clinical diagnostics cut-off value.
Anti-CEA was immobilized to the G-FET through PBASE, and subsequently the binding of CEA was
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detected by chronoamperometry. An increase in the drain current was observed, correlating with
increasing CEA concentration, as depicted in Figure 10 [47].
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Figure 10. (a) Drain-source current response at the time-dependent introduction of various
carcinoembryonic antigen (CEA) concentrations; (b) Drain-source current against CEA concentration
fitted based on Hill adsorption model. Adapted from [47], Copyright 2017, with permission
from Elsevier.
Debye–Hükel Screening
Even though many immuno-based sensors have been reported in the literature, it is still
challenging to reach ultra-high sensitivities because of Debye–Hükel screening [52]. Debye–Hükel
screening is a phenomenon caused by the solution’s interaction with the sensor [17]. Ionic solutions
effectively screen the charge of analytes in proximity with the sensor surface by forming an electron
double-layer. The length at which the analyte is able to be screened, otherwise known as the Debye
screening length (λD), is highly dependent on buffer concentration [52]. Therefore, immunoFET
detection is essentially limited to interactions which occur within a small distance of the electrode
surface. Molecules outside of the λD are generally unable to be detected, as the charges within the
graphene channel are unaffected [58]. As depicted in Figure 11, the λD decreases with increasing buffer
concentration [17]. The Debye screening phenomenon makes it difficult to develop a highly sensitive
immunosensor, as high ionic strength buffer solutions are required for biological species, therefore
decreasing the λD, and making it difficult to use antibodies as the capture molecule [52].
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and Wang et al. reported the successful detection of thrombin, a cardiovascular biomarker, using the 
aptamer based G-FET approach [36,61]. Others have reported the detection of vascular endothelial 
growth factor (VEGF), a tumour growth and metastasis biomarker [60], and bisphenol A (BPA) (a 
chemical found in packaging which is known to be hazardous to human health) [62]. 
Kim et al. reported research addressing this issue. The research directly compared the 
performance of an aptamer-based G-FET and an antibody-based G-FET for protective antigen (PA), 
a target analyte for detecting anthrax. A single-stranded DNA aptamer (PA65 5–12) and anti-PA were 
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based sensor to have an overall better performance to the antibody based sensor, as depicted in Figure 
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20 mV/decade. This indicated that the limit of detection had dropped 3 orders of magnitude when 
using the aptamer sensor as well as improving the detection range by 2 orders of magnitude [48]. 
These results were supported by the less sensitive detection of PA previously reported, which 
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Figure 11. An illustration highlighting how different ionic buffer solution concentrations affect
the screening length (λD). Green—sensor platform, purple—bioreceptor, pink—antigen. Reprinted
from [17], Copyright 2011, with permission from Elsevier.
This issue has been addressed by many by only utilizing the antigen binding fragment (Fab)
of the antibody. This decreases the distance of the antigen antibody interaction from the surface
from approximately 10–15 nm for the whole antibody to approximately 3–5 nm for the Fab, allowing
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for the use of higher ionic strength buffers [16,59]. Many have also addressed the Debye screening
phenomenon through the development of aptasensors [36,48,58,60,61]. Aptamers are short chain
peptides or single-stranded nucleic acids designed to fold into a three-dimensional (3D) structure
specifically for binding target analytes. Aptamers have attracted considerable attention due to their ease
of synthesis, high binding efficiency and affinity, specificity, and high stability. Most of all, aptamers
have been extensively researched due to their small size (less than 5 nm), which is a desirable trait to
combat the issues faced with Debye screening [14]. Both Saltzgaber and co-workers and Wang et al.
reported the successful detection of thrombin, a cardiovascular biomarker, using the aptamer based
G-FET approach [36,61]. Others have reported the detection of vascular endothelial growth factor
(VEGF), a tumour growth and metastasis biomarker [60], and bisphenol A (BPA) (a chemical found in
packaging which is known to be hazardous to human health) [62].
Kim et al. reported research addressing this issue. The research directly compared the performance
of an aptamer-based G-FET and an antibody-based G-FET for protective antigen (PA), a target
analyte for detecting anthrax. A single-stranded DNA aptamer (PA65 5–12) and anti-PA were used.
A comparison of the range of detection, sensitivity, and limit of detection proved the aptamer-based
sensor to have an overall better performance to the antibody based sensor, as depicted in Figure 12.
The aptasensor had a detection range of 12 aM to 120 fM, with a sensitivity of 30 mV/decade, whilst
the antibody-based sensor exhibited a detection range of 12 fM to 1.2 pM, with a sensitivity of
20 mV/decade. This indicated that the limit of detection had dropped 3 orders of magnitude when
using the aptamer sensor as well as improving the detection range by 2 orders of magnitude [48].
These results were supported by the less sensitive detection of PA previously reported, which showed
an antibody-based G-FET with a limit of detection of 1 fM [63].
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biosensors, with an emphasis on nucleic acid-based sensors. Label-free G-FETs have shown sensitivities
as low as attomolar, far lower than those usually exhibited by other semiconductor technologies or
current bioanalytical methods, attesting to G-FET biosensors as a potential platform towards clinical
applications. There are, however, challenges faced in the development of G-FET biosensors. One of
these limitations is device sensitivity due to the Debye–Hükel phenomenon and limited surface area.
These issues were highlighted in Section 4 of the review with examples.
The Debye–Hükel phenomenon becomes a hindrance in developing highly sensitive G-FET
biosensors, as high ionic strength buffers are needed for the analyte solutions. This decreases the Debye
screening length, and as a result decreases the sensitivity of the G-FET to target analytes outside of this
length. Therefore, although the field of G-FET technologies is rapidly improving, the development
of immunoFETs is hindered by Debye-screening. However, significant R&D efforts have focused on
bypassing this issue through the development of nucleic acid-based sensors, aptasensors, and antigen
binding fragment (Fab) modified G-FETs. The use of aptamers and Fabs as biorecognition molecules
decreases the distance of the interaction from 10–15 nm to 3–5 nm, well within the debye-screening
length of 7.4 nm that is seen for 0.01× PBS solution. The development of aptamers and Fabs have
led to a biorecognition technology which can replace antibodies and will possibly drive forward the
development of immunoFET technologies.
The second issue is the surface area of the G-FET sensor. Although graphene has an inherently high
surface area, it was reported that this feature could be further improved, and as a result the sensitivity
could be increased. This was possible through decorating the G-FET surface with metal nanoparticles,
increasing the binding sites for the biorecognition element, and therefore the target analyte.
It is clear that graphene has many superior qualities when compared to other semi-conductor
technologies. However, the majority of these measured characteristics and aforementioned G-FET
sensors have only been achieved using the highest of quality samples within a laboratory setting.
To date, most of the work has focused on R&D efforts, as although rapidly improving, these
exceptional properties still remain difficult to obtain in a mass-scale manufacturing process [64].
Deokar et al. demonstrated the high quality growth of CVD graphene that was free of residue and
contamination, which is a vital aspect needed for moving graphene-based biosensors from the lab to
industry. It is the status of these large-scale production processes which are the driving force behind the
development of graphene for commercialization [22]. Furthermore, the scalability of these processes
also remains a bottle-neck in production. However, once a “gold-standard” is reached, a growing
interest in graphene for commercialization will most likely be observed. Many challenges will need to
be faced in the commercialization of G-FETs, for example identifying routes to incorporate G-FETs into
existing technologies or commercial systems, and eventually the replacing the existing technologies
with these new concepts [64]. The Graphene Flagship initiative aims to develop consumer products
from graphene by 2025–2030. The initiative describes the process of graphene commercialization as
a hierarchy of many stages. These are understanding its properties and processes, device concepts and
proof of principle, technologies for quality wafer-scale manufacturing, prototypes, viable technologies,
and finally products. At present, graphene commercialization is in the device concept and proof
of principle stage, with few prototypes having been developed [65]. To move the development of
G-FETs forward, the proof-of-concept devices must be developed further into the prototype stage.
This has to be done by moving from testing using buffered solutions to testing the analytes in situ.
Many of the nucleic acid biosensors have been developed using synthesized short chain nucleotides.
Moving forward, longer chain nucleotides or whole genes must be considered to enable the G-FETs
developed to be applicable in clinical settings. Nonetheless, G-FETs promise to bring new and exciting
alternatives to current healthcare diagnostics.
Furthermore, to develop efficient G-FET biosensors with high accuracy, precision, reproducibility,
and lower detection limits, it is vital to improve the biomolecular immobilization strategies. Therefore,
more functionalization chemistries need to be identified. The exploration of various bioreceptors,
such as aptamers and antibody fragments, would certainly increase their sensitivity. Moreover, the
Diagnostics 2017, 7, 45 15 of 18
nano-bio interfaces in G-FET sensors should be investigated in more detail. The real-time detection
and stability of such sensors also needs to be analyzed in detail to enable the commercialization of
G-FET biosensors that exhibit long-term stability and superior performance for clinical practice.
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